New York, NY, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Cancer Biomarkers Market by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Other Biomarkers); by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer, and Other Cancer Types); by Profiling Technology (Imaging technologies, Omic Technologies (Proteomics, Genomics, and Other Omic Technologies), Cytogenetics-Based Tests, and Immunoassays); and for Application (Drug Discovery and Development, Personalized medicine, Diagnostics, and Other Applications): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024”. According to the report, global cancer biomarkers market was valued at approximately USD 11,000 million in 2017 and is expected to generate revenue of around USD 26,000 million by end of 2024, growing at a CAGR of around 13% between 2018 and 2024.
Cancer biomarkers are perceptible substances, that are used as an indicator of the biological status of the tumor and hence they are used to analyze the prognostic and diagnostic stages of cancer. The preclusion of cancer by early diagnosing and analyzing diverse cancer biomarkers using various diagnostic techniques is an insightful approach for obtaining speedy results for treatment. These biomarkers are used as menace indicators for a different type of cancers such as breast cancer, lung cancer, blood cancer, ovarian cancer, and prostate cancer, among others. SCC, CEA, NSE Cyfra 21-1, PSA, TPA, CA15-3, BRCA ½, EGF R, etc. are some of the key biomarkers which are widely used.
Browse through 95 Tables & 36 Figures spread over 140 Pages and in-depth TOC on “Global Cancer Biomarkers Market Size & Trends Report: Industry Type, Growth, Segments Analysis and Forecast, 2018 - 2024”.
Request Free Sample Report of Global Cancer Biomarkers Market Report @ https://www.zionmarketresearch.com/sample/cancer-biomarkers-market
The global cancer biomarkers market is segmented as biomarker type, cancer type, profiling technology, applications, and by geography. Based on biomarker type, the global cancer biomarkers market is segmented as genetic biomarkers, protein biomarkers, and other biomarkers. Based on the biomarker type, the protein biomarkers accounted for the topmost share in the global cancer biomarker market in the year 2017. The key factor contributing to the high share of protein biomarkers in the global market is that they have excellent potentials in cancer diagnostics, prognostics, and therapeutic & clinical applications. Moreover, they are easy to afford as they are low in cost in comparison with genetic biomarker tests. The rising focus of biotechnology companies for the new discovery of new biomarkers is also expected to fuel the growth of the segment in the global cancer biomarker market.
Based on cancer type, the market is segmented as breast cancer, colorectal cancer, lung cancer, prostate cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer, and other cancer types. By type, breast cancer accounted for the largest share followed by lung cancer owing to the high prevalence of these cancers in the global cancer biomarker market in 2017. According to the National Cancer Institute, about 268,670 new cases of breast cancer are projected in 2018, in U.S. only.
Download Free PDF Brochure of Report: https://www.zionmarketresearch.com/requestbrochure/cancer-biomarkers-market
By profiling technology, the cancer market is further segmented as imaging technologies, omic technologies, cytogenetics-based tests, and immunoassays. The omic technologies accounted for the largest share in the global cancer biomarker market in 2017. The omic technologies include genomics, proteomics, and other omic technologies. The high-throughput from omics technologies is the key factor contributing towards the high share of the segment in the global market.
Based on applications, the cancer biomarkers market is segmented as drug discovery and development, personalized medicine, diagnostics, and other applications. The diagnostics segment accounted for the largest share in the global cancer biomarker market in 2017. The growing demand for early diagnosis of cancer, acceptance of technically advanced tests, and the growing incidence of cancer are prominent factors contributing towards the high share of diagnostics segment in the cancer biomarkers market globally.
Browse the full "Cancer Biomarkers Market by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Other Biomarkers); by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer, and Other Cancer Types); by Profiling Technology (Imaging technologies, Omic Technologies (Proteomics, Genomics, and Other Omic Technologies), Cytogenetics-Based Tests, and Immunoassays); and for Application (Drug Discovery and Development, Personalized medicine, Diagnostics, and Other Applications): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024" report at https://www.zionmarketresearch.com/report/cancer-biomarkers-market
North America accounted for the largest revenue share in the global cancer biomarkers market in 2017. Presence of top pharmaceutical and biotechnology companies, high adoption of newer technology, and established healthcare infrastructure are the some of the prominent factors contributing to the large share of cancer biomarker market in North America. Moreover, government funding for research activities is expected to boost the growth of the market in the region in the near future. For instance, according to the National Cancer Institute, in the U.S. the funding for research activities in 2016, for breast cancer was USD 519.9 million, cervical cancer USD 65.6 million, colorectal cancer USD 212.2 million, leukemia USD 241.0 million, liver cancer USD 75.7 million, lung cancer USD 283.8 million, melanoma USD 142.9 million, ovarian cancer USD 95.6 million, prostate cancer USD 241.0 million, and uterine cancer USD 16.8 million. Moreover, the government is also collaborating with various research institutes to increase research on cancer and for diagnostics and treatment purpose.
In terms of growth rate, Asia Pacific is expected to register a high growth in the global cancer biomarker market in the coming years. The rising incidence of cancer, growing government support for drug development and discovery programs, and increasing awareness about biomarkers for diagnosis of cancer is expected to propel the growth of the market in the region. India, China, and Japan accounted for the topmost share in the Asia Pacific cancer biomarker market in 2017 and is expected to remain dominant in the coming future. The favorable environment for clinical trials in the Asia Pacific is expected to propel the growth of the cancer biomarker market in the region.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/cancer-biomarkers-market
The Latin America and the Middle East and Africa held the smallest share in the global cancer biomarkers market owing to lack of awareness about diagnosis advanced techniques and the high cost of treatment and diagnosis. Thus, all the aforementioned parameters are expected to propel the market growth globally.
Some of the key players in cancer biomarkers market include Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Agilent Technologies, QIAGEN, Illumina, Inc., QIAGEN, Sino Biological Inc., Merck & Co., Inc., Novartis AG, Hologic, Inc., bioMérieux SA, and Genomic Health, Inc., among others.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/2641
This report segments the global cancer biomarkers market as follows:
Global Cancer Biomarkers Market: Biomarker Type Segment Analysis
- Genetic Biomarkers
- Protein Biomarkers
- Other Cancer Biomarkers
Global Cancer Biomarkers Market: Cancer Type Segment Analysis
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Blood Cancer
- Melanoma
- Ovarian Cancer
- Liver Cancer
- Stomach Cancer
- Other Cancer Types
Global Cancer Biomarkers Market: Profiling Technology Segment Analysis
- Imaging technologies
- Omic Technologies
- Proteomics
- Genomics
- Other Omic technologies
- Cytogenetics-Based Tests
- Immunoassays
Global Cancer Biomarkers Market: Applications Segment Analysis
- Drug discovery and Development
- Personalized medicine
- Diagnostics
- Others
Global Cancer Biomarkers Market: Regional Segment Analysis
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- CRISPR Genome Editing Market: https://www.zionmarketresearch.com/report/crispr-genome-editing-market
- Cell Expansion Market: https://www.zionmarketresearch.com/report/cell-expansion-market
- Biological Safety Cabinets Market: https://www.zionmarketresearch.com/report/biological-safety-cabinets-market
- Organ preservation Market: https://www.zionmarketresearch.com/report/organ-preservation-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Blog: http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com
Contact Us:
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com
Blog: http://zmrblog.com